In conclusion, Lico-A demonstrates multi-target anticancer potential in oral squamous cell carcinoma and melanoma through Sp1 suppression, PI3K/AKT pathway blockade, and mTOR pathway modulation (Figure 1). The gene discussed is MTOR; the disease is melanoma.